Keyword: Campath

News

Sanofi's Chris Viehbacher Sees Progress in Genzyme Talks

27.01.2011 - Sanofi-Aventis has made progress in talks with U.S. bid target Genzyme and leaders of both companies may bump into each other in Davos this week, Sanofi's CEO said on Wednesday...

News

Sanofi Extends Genzyme Bid As Talks Continue

24.01.2011 - French drugmaker Sanofi-Aventis extended its snubbed $18.5 billion tender offer for U.S. biotech Genzyme for a second time as the companies continue behind-the-scenes talks to...

News

Sanofi Likely to Extend $18.5 Billion Tender Offer for Genzyme

20.01.2011 - French drugmaker Sanofi-Aventis is likely to extend its $18.5 billion tender offer for Genzyme one last time as it seeks to buy the U.S. maker of drugs for rare diseases, sources...

News

Genzyme Posts Disappointing Q4 Results; Refuses to Comment on Sanofi

12.01.2011 - Genzyme, the subject of an $18.5 billion hostile takeover bid from Sanofi-Aventis SA, posted preliminary Q4 earnings that fell short of Wall Street forecasts and cut its earnings...

News

Genzyme Acknowledges Sanofi Talks, Quick Deal Hopes Cool

11.01.2011 - Genzyme acknowledged on Monday that it was discussing a takeover deal with French drugmaker Sanofi-Aventis, but hopes for a quick agreement cooled as both sides noted differences...

News

Sanofi Considering Raising Bid for Genzyme

10.01.2011 - French drugmaker Sanofi-Aventis and Genzyme Corp are discussing options for significantly raising Sanofi's bid for the the U.S. biotech company to about $80 per share, the Wall...

News

Genzyme Argues Campath Value In Sanofi Fight

21.12.2010 - Genzyme argued that its experimental multiple sclerosis treatment will garner far higher sales than Sanofi-Aventis is projecting, as it aims to wrest a significantly higher bid...

News

Campath Clause OK For Genzyme In Sanofi Bid

30.11.2010 - Genzyme, resisting a hostile bid from Sanofi-Aventis, is open to a deal that links its value to the success of key drug Campath, the U.S. biotech's chief executive was quoted as...